Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia.

Literature DB >> 32482751

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia.

David A Sallman¹.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2020 PMID： 32482751 PMCID： PMC7271586 DOI： 10.3324/haematol.2020.249060

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

18 in total

Review 1. Current status and new treatment approaches in TP53 mutated AML.

Authors: Anthony M Hunter; David A Sallman
Journal: Best Pract Res Clin Haematol Date: 2019-05-11 Impact factor: 3.020

2. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors: Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal: Science Date: 2019-08-09 Impact factor: 47.728

3. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Authors: Sören Lehmann; Vladimir J N Bykov; Dina Ali; Ove Andrén; Honar Cherif; Ulf Tidefelt; Bertil Uggla; Jeffrey Yachnin; Gunnar Juliusson; Ali Moshfegh; Christer Paul; Klas G Wiman; Per-Ola Andersson
Journal: J Clin Oncol Date: 2012-09-10 Impact factor: 44.544

Review 4. Targeting TP53 Mutations in Myelodysplastic Syndromes.

Authors: Anthony M Hunter; David A Sallman
Journal: Hematol Oncol Clin North Am Date: 2019-12-12 Impact factor: 3.722

5. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.

Authors: Jeremy M R Lambert; Petr Gorzov; Dimitry B Veprintsev; Maja Söderqvist; Dan Segerbäck; Jan Bergman; Alan R Fersht; Pierre Hainaut; Klas G Wiman; Vladimir J N Bykov
Journal: Cancer Cell Date: 2009-05-05 Impact factor: 31.743

6. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Authors: X Peng; M-Q-Z Zhang; F Conserva; G Hosny; G Selivanova; V J N Bykov; E S J Arnér; K G Wiman
Journal: Cell Death Dis Date: 2013-10-24 Impact factor: 8.469

7. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Authors: Detlef Haase; Kristen E Stevenson; Donna Neuberg; Jaroslaw P Maciejewski; Aziz Nazha; Mikkael A Sekeres; Benjamin L Ebert; Guillermo Garcia-Manero; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Seishi Ogawa; Yasunobu Nagata; Kenichi Yoshida; Timothy A Graubert; Matthew J Walter; Alan F List; Rami S Komrokji; Eric Padron; David Sallman; Elli Papaemmanuil; Peter J Campbell; Michael R Savona; Adam Seegmiller; Lionel Adès; Pierre Fenaux; Lee-Yung Shih; David Bowen; Michael J Groves; Sudhir Tauro; Michaela Fontenay; Olivier Kosmider; Michal Bar-Natan; David Steensma; Richard Stone; Michael Heuser; Felicitas Thol; Mario Cazzola; Luca Malcovati; Aly Karsan; Christina Ganster; Eva Hellström-Lindberg; Jacqueline Boultwood; Andrea Pellagatti; Valeria Santini; Lynn Quek; Paresh Vyas; Heinz Tüchler; Peter L Greenberg; Rafael Bejar
Journal: Leukemia Date: 2019-01-11 Impact factor: 12.883

8. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.

Authors: Salih Demir; Elena Boldrin; Qian Sun; Stephanie Hampp; Eugen Tausch; Cornelia Eckert; Martin Ebinger; Rupert Handgretinger; Geertruy Te Kronnie; Lisa Wiesmüller; Stephan Stilgenbauer; Galina Selivanova; Klaus-Michael Debatin; Lüder Hinrich Meyer
Journal: Haematologica Date: 2019-05-09 Impact factor: 9.941

9. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Authors: Elsa Bernard; Yasuhito Nannya; Robert P Hasserjian; Sean M Devlin; Heinz Tuechler; Juan S Medina-Martinez; Tetsuichi Yoshizato; Yusuke Shiozawa; Ryunosuke Saiki; Luca Malcovati; Max F Levine; Juan E Arango; Yangyu Zhou; Francesc Solé; Catherine A Cargo; Detlef Haase; Maria Creignou; Ulrich Germing; Yanming Zhang; Gunes Gundem; Araxe Sarian; Arjan A van de Loosdrecht; Martin Jädersten; Magnus Tobiasson; Olivier Kosmider; Matilde Y Follo; Felicitas Thol; Ronald F Pinheiro; Valeria Santini; Ioannis Kotsianidis; Jacqueline Boultwood; Fabio P S Santos; Julie Schanz; Senji Kasahara; Takayuki Ishikawa; Hisashi Tsurumi; Akifumi Takaori-Kondo; Toru Kiguchi; Chantana Polprasert; John M Bennett; Virginia M Klimek; Michael R Savona; Monika Belickova; Christina Ganster; Laura Palomo; Guillermo Sanz; Lionel Ades; Matteo Giovanni Della Porta; Harold K Elias; Alexandra G Smith; Yesenia Werner; Minal Patel; Agnès Viale; Katelynd Vanness; Donna S Neuberg; Kristen E Stevenson; Kamal Menghrajani; Kelly L Bolton; Pierre Fenaux; Andrea Pellagatti; Uwe Platzbecker; Michael Heuser; Peter Valent; Shigeru Chiba; Yasushi Miyazaki; Carlo Finelli; Maria Teresa Voso; Lee-Yung Shih; Michaela Fontenay; Joop H Jansen; José Cervera; Yoshiko Atsuta; Norbert Gattermann; Benjamin L Ebert; Rafael Bejar; Peter L Greenberg; Mario Cazzola; Eva Hellström-Lindberg; Seishi Ogawa; Elli Papaemmanuil
Journal: Nat Med Date: 2020-08-03 Impact factor: 53.440

10. Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.

Authors: Thomas Cluzeau; Alix Dubois; Arnaud Jacquel; Frederic Luciano; Aline Renneville; Claude Preudhomme; Jean Michel Karsenti; Nicolas Mounier; Pierre Rohrlich; Sophie Raynaud; Bernard Mari; Guillaume Robert; Patrick Auberger
Journal: Oncotarget Date: 2014-06-30

4 in total

1. Whom should we treat with novel agents? Specific indications for specific and challenging populations.

Authors: Lindsay Wilde; Margaret Kasner
Journal: Hematology Am Soc Hematol Educ Program Date: 2021-12-10

Review 2. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

Authors: Liz J Hernández Borrero; Wafik S El-Deiry
Journal: Biochim Biophys Acta Rev Cancer Date: 2021-04-29 Impact factor: 11.414

3. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

Authors: James A McCubrey; Akshaya K Meher; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Michelle M LaHair; Richard A Franklin; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemysław Duda; Agnieszka Gizak
Journal: Aging (Albany NY) Date: 2022-04-27 Impact factor: 5.682

4. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.

Authors: Arnab Ghosh; Judith Michels; Riccardo Mezzadra; Divya Venkatesh; Lauren Dong; Ricardo Gomez; Fadi Samaan; Yu-Jui Ho; Luis Felipe Campesato; Levi Mangarin; John Fak; Nathan Suek; Aliya Holland; Cailian Liu; Mohsen Abu-Akeel; Yonina Bykov; Hong Zhong; Kelly Fitzgerald; Sadna Budhu; Andrew Chow; Roberta Zappasodi; Katherine S Panageas; Olivier de Henau; Marcus Ruscetti; Scott W Lowe; Taha Merghoub; Jedd D Wolchok
Journal: J Clin Invest Date: 2022-09-15 Impact factor: 19.456

4 in total